We want to share our experience with accreditations that brought us to be a reliable centre for CAR T Cells administration.
Methods: Our Transplant Centre Applied for CNT/CNS accreditation in 2015. Regular meetings led to the implementation of processes and procedures. After a first Inspection in February 2015 with a first report, a strict collaboration with the Hospital Direction allowed the development of a CAPA (Corrective Action and Preventive Action) plan. Moreover, thanks to the presence in the staff of three JACIE Inspector and a Quality Facilitator we avoided the need of external consultants and so less outgoings for the public health corporation.
The Onco-Hematology Pediatric Unit applied as well to become a centre habilitated to perform clinical trials Phase I.
Again, waiting for the Institutional Inspection, an integrated path of continuous improvement was implemented with the aim to guarantee safety and well-being enrolled patients and adequate Study conduction following Standard GCP/ICH (Good Clinical Practice/ International Conference on Harmonization).
A working group was created with the representatives of the operational units involved, the related hospital Our Unit mindful of the previous accreditation process could profit of human resources and a translational competence experience in the field of a quality system.
Results: We obtained CNT/CNS Certification in 2017 and the same year the GCP inspections office sent two inspectors to assess the compliance of the centre with respect to the AIFA Determina. The inspection team valued the measures implemented produced by the centre and concluded the inspection process.
The centre of Onco-Haematology Paediatric of S. Orsola Malpighi Policlinic of Bologna has been the first certified by the competent Authority AIFA for clinical trials Phase I.
Conclusions: The active cooperation of the OncoHaematology Paediatric Unit and its Transplant Centre with the Hospital Administration and Services group was a winning strategy to gain different accreditations as CNT/ CNS and certification for Phase1 Clinic studies.
The both Accreditation make the centre reliable for administration of ATMPs as Car-T-cells on Paediatric patients as demanded by European Status.
Disclosure: Nothing to declare Background: Peripheral blood hematopoietic stem cells (PBSC) are collected using an apheresis machine after being mobilized from the bone marrow to the blood. CD34+ cell count (mln/kg of recipient body weight) in the final product is used to determine sufficient amount of PBSC for stem cell transplantation (SCT). Target PBSC dose in allogeneic SCT setting varies among different TC, usually between 3-5mln/kg, but requested dose is crucial for successful SCT. CD34+ cell count is always calculated after PBSC collection in CCs and usually recalculated in TC after cells delivery. In case of unrelated donor (UD) donation PBSC are collected in different CCs all over the world using different techniques of cell calculation which might be the cause of cell count differences between CCs and TC.
VULSK recalculate quantity of CD34+ cells in all PBSC products delivered from CCs as one of quality parameters by flow cytometry ISHAGE platform.
Research objective: To compare CD34 + cell counting results between CCs and TC at VULSK.
Methods: CD34 + cell counts of all PBSC products from UD, collected and calculated in different CCs (including CCs in Poland, Germany, Denmark, Austria, Israel, USA, Great Britain and Singapore) and recalculated at TC at VULSK during 2015-2018 October were retrospectively analyzed. Results obtained at different CCs and TC were compared. Percentage difference of original value was calculated. CD34+ cells counts were expressed in mln/ kg. SPSS program for statistical analysis was used. The differences were considered statistically significant at p ≤ 0.05.
Results: 118 UD PBSC records were analyzed. Median of CD34+ cells mln/kg counts was 7.93 (2.66-24.30) calculated at CCs and 7.3 (1.43-23.52) at TC. In 86 cases CD34 count was calculated lower in TC than CCs (percentage of difference 0-171%) and in 32 cases TC obtained higher CD34+ values than CCs (0-59%). Results are accepted to be comparable when percentage difference does not exceed 10%. 42.4 % (n = 50) of cases were within this range. 57.6% (n = 68) of cases exceeded limit of 10% difference. The median percentage difference in cell count between CCs and TC was 13% (0-171%). Only 11% (n = 13) of calculations differed more than 50% and only 3.4% (n = 4) more than 100%. Those 4 cases were analyzed separately: CD34+ cell counts in CCs and TC was calculated 5.9 and 2.18, 8.07 and 3.8, 7.03 and 2.76, 7.04 and 3.48 respectively. All of 4 cases showed significantly lower CD34+ counts calculated in TC than in CCs and two were below lower than 3 mln/kg, but none of them affected clinical engraftment. No significant differences were found comparing CD34+ counts between particular CCs and TC.
Conclusions: The median percentage difference in cell count between CCs and TC was 13%, which is close to acceptable 10% value. However a few calculations differed more than 100%. CD34+ counts should be always monitored after PBSC product delivery as one of quality control parameters. Cases with significant differences in cell counts should be analyzed specifically.
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